AC Immune (NASDAQ:ACIU) issued an update on its Phase 2 drug candidates for the treatment of Alzheimer’s and Parkinson diseases and said it has extended its cash runway into 2026 through a $50M equity...
Source LinkAC Immune (NASDAQ:ACIU) issued an update on its Phase 2 drug candidates for the treatment of Alzheimer’s and Parkinson diseases and said it has extended its cash runway into 2026 through a $50M equity...
Source Link
Comments